315 related articles for article (PubMed ID: 35165832)
1. Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
Upadhya B; Kozak PM; Stacey RB; Vasan RS
Curr Hypertens Rep; 2022 Jan; 24(1):1-20. PubMed ID: 35165832
[TBL] [Abstract][Full Text] [Related]
2. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
[TBL] [Abstract][Full Text] [Related]
3. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
4. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy.
Yandrapalli S; Khan MH; Rochlani Y; Aronow WS
Ther Adv Cardiovasc Dis; 2018 Aug; 12(8):217-231. PubMed ID: 29921166
[TBL] [Abstract][Full Text] [Related]
6. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
8. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
9. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Liu RC
Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
11. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J
Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Dargad RR; Prajapati MR; Dargad RR; Parekh JD
Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
[TBL] [Abstract][Full Text] [Related]
13. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
14. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Kario K
Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
16. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
[TBL] [Abstract][Full Text] [Related]
17. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
18. Valsartan: more than a decade of experience.
Black HR; Bailey J; Zappe D; Samuel R
Drugs; 2009; 69(17):2393-414. PubMed ID: 19911855
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor-neprilysin inhibitors for hypertension-hemodynamic effects and relevance to hypertensive heart disease.
Kario K; Williams B
Hypertens Res; 2022 Jul; 45(7):1097-1110. PubMed ID: 35501475
[TBL] [Abstract][Full Text] [Related]
20. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]